{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:18:02Z","timestamp":1788023882544,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,29]]},"DOI":"10.7759\/cureus.115403","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:35:52Z","timestamp":1788021352000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Erenumab in the Preventive and Therapeutic Treatment of Patients Suffering From Migraine"],"prefix":"10.7759","author":[{"given":"Yatri","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwa","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshini  S","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankhuri","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2018-0037","article-title":"Erenumab in the treatment of migraine","volume":"8","author":"Jain S","year":"2018","unstructured":"Jain S, Yuan H, Spare N, Silberstein SD. Erenumab in the treatment of migraine. Pain Manag. 2018, 8:415-26. 10.2217\/pmt-2018-0037","journal-title":"Pain Manag"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018, 38.1-211. 10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/head.12505_2","article-title":"Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention","volume":"55 Suppl 2","author":"Lipton RB","year":"2015","unstructured":"Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015, 55 Suppl 2:103-22; quiz 123-6. 10.1111\/head.12505_2","journal-title":"Headache"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000199","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein SD","year":"2015","unstructured":"Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015, 21:973-89. 10.1212\/CON.0000000000000199","journal-title":"Continuum (Minneap Minn)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00631.x","article-title":"Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study","volume":"47","author":"Diamond S","year":"2007","unstructured":"Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007, 47:355-63. 10.1111\/j.1526-4610.2006.00631.x","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby PJ","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990, 28:183-7. 10.1002\/ana.410280213","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410368444","article-title":"Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura","volume":"30","author":"Hansen JM","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010, 30:1179-86. 10.1177\/0333102410368444","journal-title":"Cephalalgia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho TW","year":"2010","unstructured":"Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010, 6:573-82. 10.1038\/nrneurol.2010.127","journal-title":"Nat Rev Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007452","article-title":"Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study","volume":"92","author":"Lipton RB","year":"2019","unstructured":"Lipton RB, Tepper SJ, Reuter U, et al.. Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology. 2019, 92:e2250-60. 10.1212\/WNL.0000000000007452","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/head.14536","article-title":"Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: a subgroup analysis","volume":"63","author":"Tepper SJ","year":"2023","unstructured":"Tepper SJ, Lipton RB, Silberstein SD, et al.. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: a subgroup analysis. Headache. 2023, 63:730-42. 10.1111\/head.14536","journal-title":"Headache"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418789072","article-title":"Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab","volume":"38","author":"Buse DC","year":"2018","unstructured":"Buse DC, Lipton RB, Hallstr\u00f6m Y, et al.. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018, 38:1622-31. 10.1177\/0333102418789072","journal-title":"Cephalalgia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.799","article-title":"Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine","volume":"103","author":"de Hoon J","year":"2018","unstructured":"de Hoon J, Van Hecken A, Vandermeulen C, et al.. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018, 103:815-25. 10.1002\/cpt.799","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Sun H","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S, et al.. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016, 15:382-90. 10.1016\/S1474-4422(16)00019-3","journal-title":"Lancet Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby PJ","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al.. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017, 377:2123-32. 10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper S","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, et al.. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017, 16:425-34. 10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick DW","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al.. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018, 38:1026-37. 10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter U","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018, 392:2280-7. 10.1016\/S0140-6736(18)32534-0","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/head.13652","article-title":"A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults","volume":"59","author":"Sakai F","year":"2019","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, et al.. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache. 2019, 59:1731-42. 10.1111\/head.13652","journal-title":"Headache"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0944-0","article-title":"Erenumab: first global approval","volume":"78","author":"Markham A","year":"2018","unstructured":"Markham A. Erenumab: first global approval. Drugs. 2018, 78:1157-61. 10.1007\/s40265-018-0944-0","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt T","year":"2018","unstructured":"Schwedt T, Reuter U, Tepper S, et al.. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018, 19:92. 10.1186\/s10194-018-0923-6","journal-title":"J Headache Pain"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01069-1","article-title":"Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety","volume":"79","author":"Lattanzi S","year":"2019","unstructured":"Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019, 79:417-31. 10.1007\/s40265-019-01069-1","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/head.14423","article-title":"Different dosage regimens of erenumab for the treatment of migraine: a systematic review and meta-analysis of the efficacy and safety of randomized controlled trials","volume":"62","author":"Gui T","year":"2022","unstructured":"Gui T, Li H, Zhu F, Wang Q, Zhou X, Xue Q. Different dosage regimens of erenumab for the treatment of migraine: a systematic review and meta-analysis of the efficacy and safety of randomized controlled trials. Headache. 2022, 62:1281-92. 10.1111\/head.14423","journal-title":"Headache"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018483","article-title":"Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials","volume":"98","author":"Zhu C","year":"2019","unstructured":"Zhu C, Guan J, Xiao H, Luo W, Tong R. Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2019, 98:e18483. 10.1097\/MD.0000000000018483","journal-title":"Medicine (Baltimore)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666210823104916","article-title":"Optimal dose of erenumab for preventive treatment of episodic migraine: a systematic review and meta-analysis","volume":"20","author":"Yang Y","year":"2022","unstructured":"Yang Y, Chen M, Wu D, Sun Y, Jiang F, Chen Z, Wang Z. Optimal dose of erenumab for preventive treatment of episodic migraine: a systematic review and meta-analysis. Curr Neuropharmacol. 2022, 20:460-70. 10.2174\/1570159X19666210823104916","journal-title":"Curr Neuropharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13005-025-00494-w","article-title":"Unveiling the efficacy and safety of erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis","volume":"21","author":"Haseeb ME","year":"2025","unstructured":"Haseeb ME, Mohammed HE, Yaser H, Hanen G, Nasser M, Yaser S, Bady Z. Unveiling the efficacy and safety of erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis. Head Face Med. 2025, 21:19. 10.1186\/s13005-025-00494-w","journal-title":"Head Face Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/502577-efficacy-and-safety-of-erenumab-in-the-preventive-and-therapeutic-treatment-of-patients-suffering-from-migraine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:35:54Z","timestamp":1788021354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/502577-efficacy-and-safety-of-erenumab-in-the-preventive-and-therapeutic-treatment-of-patients-suffering-from-migraine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.115403","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}